"ProC Global": A functional screening test that predicts recurrent venous thromboembolism

Summary

Abnormalities of the Protein C (PC) pathway are found in the majority of patients with thrombophilia. ProC Global is a coagulation assay that reflects the net effect of the PC pathway by measuring the activated partial thromboplastin time (APTT) of patient and control plasma, before and after activation of endogenous PC by Protac, a snake venom. Previous studies have suggested that abnormalities in this test are associated with an increased risk of venous thromboembolism (VTE). A retrospective analysis was performed using frozen plasma samples from 140 patients with confirmed VTE to determine whether an abnormal ProC Global result (in the presence and in the absence of known abnormalities in the PC pathway) is a predictor of initial and recurrent VTE. Patients were tested for the presence of activated protein C resistance, Factor V Leiden, PC and protein S (PS) deficiency, and non-specific inhibitor positivity. Mean ProC Global results were significantly lower in patients with recurrent VTE than in patients without recurrent VTE. The association between abnormal ProC Global result and recurrent VTE showed a strong trend, before (odds ratio, OR 3.6) and after (OR 3.1) exclusion of known thrombophilic abnormalities. Patients with a first episode of idiopathic VTE also expressed significant lower ProC Global results than those with secondary VTE. After exclusion of known PC pathway abnormalities, there was a statistically significant association between abnormal ProC Global and initial idiopathic VTE (p=0.04). These results suggest that ProC Global may serve as a predictor of recurrent VTE and potentially for first episode of idiopathic VTE. ProC Global may help identify patients at increased risk of initial and recurrent VTE.

Keywords

ProC Global - plasma assay - thrombophilia - venous thromboembolism - recurrence

• References

• 1 Lane DA, Mannucci PM, Bauer KA. et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-34.
• 2 Salomon O, Steinberg DM, Zivelin A. et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-8.
• 3 Kearon C, Gent M, Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
• 4 Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism Research Committee of the British Thoracic Society. Lancet 1992; 340: 873-6.
• 5 Levine MN, Hirsh J, Gent M. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
• 6 Koster T, Rosendaal FR, de Ronde H. et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
• 7 Griffin JH, Evatt B, Wideman C. et al. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
• 8 Heijboer H, Brandjes DP, Buller HR. et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-6.
• 9 Kraus M, Noah M, Fickenscher K. The PCAT--a simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res 1995; 79: 217-22.
• 10 Robert A, Eschwege V, Hameg H. et al. Anticoagulant response to Agkistrodon contortrix venom (ACV test): a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost 1996; 75: 562-6.
• 11 Toulon P, Perez P, Demay Y. et al. ProC Global: a new assay to evaluate the functionality of the protein C anticoagulant pathway. Preliminary results in 223 consecutive patients with a history of venous thromboembolism. Fibrinolysis Proteolysis 1998; 12: 347-52.
• 12 Dati F, Hafner G, Erbes H. et al. ProC Global: the first functional screening assay for the complete protein C pathway. Clin Chem 1997; 43: 1719-23.
• 13 Dragoni F, Tormene D, Simioni P. et al. ProC global: a new automated screening assay for the evaluation of total function of the protein C system. Clin Appl Thromb Hemost 2001; 7: 351-5.
• 14 Rimmer JE, Cooper PC, Brookfield CJ. et al. Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway. Clin Lab Haematol 2000; 22: 351-4.
• 15 Robert A, Aillaud MF, Eschwege V. et al. Screening for identified and unidentified protein C pathway defects by the Agkistrodon contortrix venom test in consecutive patients. Am J Clin Pathol 1999; 112: 233-7.
• 16 Toulon P, Adda R, Perez P. Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolism. Thromb Res 2001; 104: 93-103.
• 17 Gemmati D, Serino ML, Tognazzo S. et al. The reduced sensitivity of the ProC Global test in protein S deficient subjects reflects a reduction in the associated thrombotic risk. Blood Coagul Fibrinolysis 2001; 12: 691-7.
• 18 Crowther MA, Roberts J, Roberts R. et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001; 85: 390-4.
• 19 Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
• 20 Low-molecular-weight heparin in the treatment of patients with venous thromboembolism The Columbus Investigators. N Engl J Med 1997; 337: 657-62.
• 21 Rimmer JE, Cooper PC, Brookfield CJ. et al. Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway. Clin Lab Haematol 2000; 22: 351-4.
• 22 Toulon P, Halbmeyer WM, Hafner G. et al. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation. Blood Coagul Fibrinolysis 2000; 11: 447-54.
• 23 Engel H, Zwang L, van Vliet HH et al. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost 1996; 75: 267-9.
• 24 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 25 Martinoli JL, Stocker K. Fast functional protein C assay using Protac, a novel protein C activator. Thromb Res 1986; 43: 253-64.
• 26 Deutz-Terlouw PP, Ballering L, van Wijngaarden A. et al. Two ELISA's for measurement of protein S, and their use in the laboratory diagnosis of protein S deficiency. Clin Chim Acta 1990; 186: 321-34.
• 27 Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticaogulants. Thromb Haemost 1995; 74: 1597-603.
• 28 Rosendaal FR, van der Meer FJM, Visser TH. et al. ProC Global screening test and the risk of thrombosis. Thromb Haemost 1999; 82 (suppl) 731
• 29 Zotz RB, Gerhardt A, Scharf RE. ProC Global assay is an independent predictor for venous thromboembolism. Blood 1998; Abstract 174
• 30 Lewis MR, Callas PW, Jenny NS. et al. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 2001; 86: 1495-500.
• 31 Huisman MV, Buller HR, ten Cate JW. et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep vein thrombosis. Chest 1989; 95: 498-502.
• 32 Kyrle PA, Minar E, Hirschl M. et al. High plasma levels of factor VIIII and the risk of recurrent thromboembolism. N Engl J Med 2000; 343: 457-62.
• 33 Cristina L, Cosmi B, Michela C. et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. Br J Haematol 2004; 124: 504-10.